Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Included studies.

From: Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials

  

METHODS

PARTICIPANTS

INTERVENTIONS

OUTCOMES

INCLUDED STUDIES (date of publication)

Randomised

Double-blind

Three+ arm study

Duration (weeks)

Only Schizophrenia

History

Total number of participants

Age (years)

Sex

CPZ dose (mg/day)

Number allocated CPZ

Number allocated placebo

Leaving the study early

Global improvement

Mental State

Side-effects

Global clinical state

Behaviour

Relapse

1955

Hall

●

●

 

9

●

C

175

20–59

M+F

750 max

87

88

●

●

 

●

 

●

 
 

Vaughan

●

●

 

U/K

 

C

48

M = 43

F

75–450

24

24

 

●

     

1956

Shepherd

●

U/K

●

6

●

C

24

27–52

F

300

8

8

●

●

     

1958

Abrams

●

  

4

●

C

40

20–55

F

200–600

20

20

●

      
 

Grygier

●

U/K

 

24

●

C

30

m = 50

F

150

15

15

 

●

     
 

Hine

●

●

 

20

●

C

22

30–50

F

750 max

11

11

●

●

 

●

   
 

Simon

●

 

●

4

 

U/K

80

m = 31

U/K

200–1200

20

0

●

      

1959

Baker

●

●

●

5

 

C

25

33–79

F

150–300

7

7

●

●

●

●

   
 

Flemming

●

●

●

26

●

C

63

m = 58

F

75–300

21

21

●

  

●

 

●

 
 

Walsh

●

U/K

●

8

●

C

66

27–50

F

75–300

22

22

 

●

 

●

   

1960

Englhardt

●

●

●

78

●

U/K

173

18–40

U/K

50–800

62

56

●

     

●

 

Hamilton

●

●

●

8

●

C

54

m = 38

M

300

18

18

●

  

●

   
 

Payne

●

●

●

6

●

C

21

23–73

M

25–100

7

7

   

●

   
 

Somerville

●

●

●

6

 

C+A

60

24–58

F

200–800

15

30

●

●

 

●

 

●

 

1961

Clark

●

●

●

24

●

C

60

26–52

F

200–800

20

20

 

●

 

●

   
 

Lorr

●

●

●

12

 

A

308

<50

M

50–100

63

61

●

      
 

Kurland

●

●

●

6

 

A

277

18–61

M+F

300

33

72

●

●

 

●

   
 

Schiele

●

●

●

16

●

C

80

m = 80

M

200–1000

20

20

●

 

●

●

●

  
 

Smith

●

●

●

14

●

C

30

m = 42

M+F

150–600

13

15

     

●

 

1963

Bishop

●

●

●

10

●

C

30

U/N

M+F

800

10

10

●

●

     
 

Fink

●

U/K

●

6

 

S

311

m = 31

M+F

1200

51

44

●

      

1964

NIMH

●

●

●

6

●

A

463

16–45

M+F

200–1600

112

125

●

      

1966

Reardon

●

●

●

4

●

A

34

U/K

M+F

300–600

11

12

●

●

     
 

Saretsky

●

●

 

12

●

A

40

<55

M

400

20

20

●

      

1967

Clark

●

●

 

10

●

C

72

25–55

F

678 m

51

21

●

      
 

Letemendia

●

●

 

39

 

C

28

<65

M

300

14

14

●

      

1968

Clark a

●

●

●

14

●

C

72

20–60

F

1000 max

18

36

●

●

 

●

   
 

Clark b

●

●

●

16

●

C

69

20–60

F

1000 max

23

23

●

  

●

   
 

Cohen

●

●

●

60

●

C

126

18–42

M+F

180

42

42

●

      
 

Prien

●

●

●

24

●

C

838

19–55

M+F

2000

208

212

 

●

 

●

●

●

●

           

300

208

        

1969

Tetreault

●

●

●

12

●

C

45

m = 50

F

300–600

15

15

●

 

●

●

 

●

 

1970

Clark a

●

●

●

12

●

C

44

22–55

M+F

200–1000

15

14

●

●

 

●

●

●

 
 

Clark b

●

 

●

24

●

C

71

21–60

F

150–600

54

18

●

  

●

 

●

 

1971

Clark

●

●

●

4

●

C

86

21–45

M+F

200–1000

23

21

●

●

 

●

   

1972

Clark

●

●

●

12

●

C

55

21–60

M+F

1000

19

18

●

●

 

●

●

  
 

Serafetinedes

●

●

●

12

●

C

57

21–61

M+F

1000 max

14

13

●

●

 

●

   

1973

Hogarty

●

●

 

156

●

S

374

18–53

M+F

270 m

192

182

●

     

●

 

Klein

●

●

 

6

●

 

88

17–61

M+F

300–1200

46

42

●

      

1974

Reschke

●

●

●

0.1

●

A

50

19–57

M+F

25 im

10

11

●

●

 

●

   

1975

Ban

●

●

●

12

●

C+A

30

17–46

M+F

200–800

10

10

●

●

     
 

Hamill

●

  

0.7

●

A

44

18–55

M+F

306–475

22

22

●

      

1977

Clark

●

●

●

12

●

C

27

23–61

M+F

1000

9

9

●

●

 

●

   
 

Spohn

●

●

 

6+

●

U/K

40

18–55

M+F

200 min

20

20

      

●

1978

Rappaport

●

  

U/K

●

A

127

16–40

M

300–900

53

74

●

     

●

1981

Peet

●

●

●

12

●

U/K

53

m = 51

M+F

400 max

16

18

●

  

●

  

●

1982

Nishikawa

●

●

●

156

●

S

55

m = 33

M+F

75

10

10

      

●

1986

Zuoze

●

 

●

4

●

C

60

m = 36

U/K

450 m

20

20

    

●

  

1990

Chouinard

●

●

●

4

●

A

62

19–62

M+F

300–1200

21

21

●

●

 

●

 

●

 

1991

Borison

●

●

●

4

●

A

30

22–58

M

400–1600

9

10

  

●

 

●

  

2000

Cooper

●

●

●

8

●

C

159

18–42

M+F

600

53

53

●

●

●

    
  1. Key: ● = Yes; U/K = Unknown; C = Chronic; A = Acute; M = Male; F = Female; m = Mean; im = Intramuscular injection.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us